Eberhard-Karls-University publish series of p38 inhibitors « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Eberhard-Karls-University publish series of p38 inhibitors

Posted on June 26, 2008 by crimsoncanary

In this weeks JMC Eberhard-Karls-University publish a series of 2,4,5- and 1,2,4,5-substituted 2-thioimidazole p38 MAP kinase inhibitors

Filed under: kinase | Tagged: MAP, p38, Preclinical, Research, Synthesis

« Axelar initiate Phase I/II trial with IGF-1R drug AXL1717 Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Panitumumab »